Anavex Life Sciences (AVXL) Competitors $9.40 +0.04 (+0.43%) Closing price 04:00 PM EasternExtended Trading$9.37 -0.03 (-0.31%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL vs. TLX, SRRK, ARWR, VKTX, AMRX, XENE, KYMR, CRNX, RARE, and MORShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Telix Pharmaceuticals (TLX), Scholar Rock (SRRK), Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. Its Competitors Telix Pharmaceuticals Scholar Rock Arrowhead Pharmaceuticals Viking Therapeutics Amneal Pharmaceuticals Xenon Pharmaceuticals Kymera Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys Anavex Life Sciences (NASDAQ:AVXL) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Which has stronger valuation & earnings, AVXL or TLX? Telix Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.57-16.49Telix Pharmaceuticals$637.77M4.81$32.93MN/AN/A Is AVXL or TLX more profitable? Telix Pharmaceuticals' return on equity of 0.00% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -45.67% -40.21% Telix Pharmaceuticals N/A N/A N/A Do insiders & institutionals hold more shares of AVXL or TLX? 31.6% of Anavex Life Sciences shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AVXL or TLX? In the previous week, Telix Pharmaceuticals had 10 more articles in the media than Anavex Life Sciences. MarketBeat recorded 15 mentions for Telix Pharmaceuticals and 5 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.37 beat Telix Pharmaceuticals' score of -0.33 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate AVXL or TLX? Anavex Life Sciences presently has a consensus target price of $44.00, suggesting a potential upside of 368.09%. Telix Pharmaceuticals has a consensus target price of $22.33, suggesting a potential upside of 146.50%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Telix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Telix Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryTelix Pharmaceuticals beats Anavex Life Sciences on 6 of the 11 factors compared between the two stocks. Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$807.37M$3.16B$5.78B$9.93BDividend YieldN/A2.28%6.67%4.52%P/E Ratio-16.4921.1075.6726.68Price / SalesN/A464.37553.74213.18Price / CashN/A45.1137.1158.92Price / Book6.629.8611.446.09Net Income-$43M-$53.47M$3.28B$266.14M7 Day Performance-2.49%2.89%0.84%0.27%1 Month Performance-13.68%8.62%7.15%4.13%1 Year Performance69.06%13.69%59.66%23.92% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.9612 of 5 stars$9.40+0.4%$44.00+368.1%+66.5%$807.37MN/A-16.4940Positive NewsTLXTelix PharmaceuticalsN/A$9.55-5.9%$22.33+133.9%N/A$3.23B$516.72M0.00N/AHigh Trading VolumeSRRKScholar Rock4.6295 of 5 stars$32.65-1.9%$45.75+40.1%+269.5%$3.14BN/A-11.22140News CoveragePositive NewsARWRArrowhead Pharmaceuticals4.2165 of 5 stars$22.03-1.4%$43.14+95.8%+16.8%$3.05B$3.55M-17.21400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionVKTXViking Therapeutics4.4974 of 5 stars$27.05-1.9%$86.92+221.3%-54.3%$3.04BN/A-17.6820Positive NewsAMRXAmneal Pharmaceuticals3.257 of 5 stars$9.56+0.1%$11.60+21.3%+12.5%$3.00B$2.79B956.967,600News CoveragePositive NewsXENEXenon Pharmaceuticals3.2421 of 5 stars$38.71+0.3%$53.20+37.4%-4.7%$2.98B$9.43M-10.90210News CoveragePositive NewsAnalyst ForecastOptions VolumeKYMRKymera Therapeutics3.4946 of 5 stars$41.20-1.3%$58.76+42.6%-8.6%$2.95B$44.71M-11.87170News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.8267 of 5 stars$30.99+1.1%$68.86+122.2%-35.1%$2.92B$1.39M-7.54210News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.5398 of 5 stars$29.96-1.1%$81.50+172.0%-44.3%$2.89B$560.23M-5.421,310News CoveragePositive NewsAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies TLX Alternatives SRRK Alternatives ARWR Alternatives VKTX Alternatives AMRX Alternatives XENE Alternatives KYMR Alternatives CRNX Alternatives RARE Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVXL) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
